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background:  An economic model was developed to compare the medical resource cost and health outcome effects of physiology-guided 
management with FFR compared with standard angiography-guided management in patients with non-ST elevation myocardial infarction 
based on participants British Heart Foundation FAMOUS-NSTEMI pilot trial (NCT01764334).
methods:  Costs and health effects were estimated as a function of care received (CABG, PCI or medical therapy [MT]) using adjusted, 
marginal predictions from statistical models. Health effects were expressed as quality-adjusted life-years (QALYs), estimated from 
individual EQ-5D responses. Resource utilisation was prospectively recorded from randomisation to 12 months. Results were extended 
from the within-trial period to the lifetime using a simple extrapolation model.
Results:  350 NSTEMI patients were prospectively assigned to FFR guided (n=176) or angiography-guided (n=174) management. Within-
trial costs were highest for those patients who received CABG followed by PCI and then medical therapy. However, within-trial QALYs were 
lowest for patients who received MT. On average over the lifetime, compared to standard care, FFR resulted in 0.01 additional QALYs at a 
cost savings of £236.
conclusion:  FFR showed the potential to reduce health service costs through reducing interventional procedures and increasing the use 
of MT. A future definitive trial should focus on health outcomes to ensure that FFR achieves its potential.
CABG MT PCI
Trial costs (£) 18,978 (16,870 - 21,243) 6,145 (5,230 - 7,168) 7,955 (7,118 - 8,918)
Trial QALYs 0.79 (0.71 - 0.87) 0.77 (0.71 - 0.82) 0.80 (0.77 - 0.83)
